The combination of bulevirtide plus peginterferon alfa-2a is superior to
bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV)
RNA level at 24 weeks after the end of treatment in patients with chronic
hepatitis D,
according to a study published online June 6 in the New
England Journal of Medicine to coincide with the annual congress of the
European Association for the Study of the Liver, held from June 5 to 8 in Milan.